Cardiff Oncology, Inc. (CRDF)

USD 4.49

(-16.07%)

Market Cap (In USD)

298.66 Million

Revenue (In USD)

488 Thousand

Net Income (In USD)

-41.44 Million

Avg. Volume

553.67 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.41-6.42
PE
-
EPS
-
Beta Value
1.928
ISIN
US14147L1089
CUSIP
14147L108
CIK
1213037
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Mark Erlander Ph.D.
Employee Count
-
Website
https://www.cardiffoncology.com
Ipo Date
2004-07-27
Details
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.